United Therapeutics Corp. (UTHR), a public benefit corporation, announced Monday that the U.S. Food and Drug Administration (FDA) has ...
UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...
United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...
Sarcomatrix Therapeutics, Corp Logo Company Prepares for Phase 1 Clinical Trials of Lead Candidate S-969 in 2025 Our robust preclin ...
United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...
Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...
Corporation (NASDAQ: UTHR) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a pioneering clinical trial of its gene-edited xenotransplantation kidney, named UKidney, ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
On February 3rd, our Board of Directors approved another tax-efficient share repurchase program of up to 10% of our total shares outstanding, expected to be executed over the next three to six months.
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that the U.S. Food and Drug Administration ( FDA ) has cleared its Investigational N ...
His effort paid off: Tim Andrews, 66, is only the second person known to be living with a pig kidney. Andrews is free from dialysis, Massachusetts General Hospital announced Friday, and recovering so ...